Stoke Therapeutics, Inc. (STOK) Tops Q4 EPS by 37c
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Join SI Premium – FREE
Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q4 EPS of ($0.18), $0.37 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $22.61 million versus the consensus estimate of $4.1 million.
For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
- Cantor Fitzgerald Starts Nuvation Bio Inc (NUVB) at Overweight
- ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
